SEC Form 4 · accession 0001437749-26-023440
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Krempa
Officer — Chief Business Officer
Period of report
Jul 12, 2026
Accepted (ET)
Jul 13, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 12, 2026 | M | 10,000 | — | A | 37,025 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Jul 12, 2026 | M | 10,000 | D | — | — | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1On July 12, 2022, the reporting person was granted 40,000 restricted stock units which vested in four equal annual installments beginning July 12, 2023.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.